{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447582270
| IUPAC_name = (''RS'')-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate
| image = Naftidrofuryl.svg

<!--Clinical data-->
| tradename = Praxilene 
| Drugs.com = {{drugs.com|international|naftidrofuryl}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM 
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = [[Liver|Hepatic]] 
| elimination_half-life = 1 - 3.5 hours 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 31329-57-4
| ATC_prefix = C04
| ATC_suffix = AX21
| PubChem = 4417
| ChEMBL = 1620794
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4264
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 42H8PQ0NMJ

<!--Chemical data-->
| C=24 | H=33 | N=1 | O=3 
| molecular_weight = 383.524 g/mol
| smiles = O=C(OCCN(CC)CC)C(Cc2c1ccccc1ccc2)CC3OCCC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KBAFPSLPKGSANY-UHFFFAOYSA-N
}}

'''Naftidrofuryl''' ([[International Nonproprietary Name|INN]]), also known as '''nafronyl''' or as the [[oxalate]] salt '''naftidrofuryl oxalate''' or '''nafronyl oxalate''', is a [[vasodilator]] used in the management of peripheral and [[Cerebrum|cerebral]] [[Blood vessel|vascular]] disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective [[receptor antagonist|antagonist]] of [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s (with action as an [[inverse agonist]] of the [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] specifically characterized).<ref name="LanzerTopol2013">{{cite book|author1=Peter Lanzer|author2=Eric J. Topol|title=Pan Vascular Medicine: Integrated Clinical Management|url=https://books.google.com/books?id=B8LsCAAAQBAJ&pg=PA1394|date=20 December 2013|publisher=Springer|isbn=978-3-642-56225-9|pages=1394–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA147|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=147–}}</ref><ref name="AlyHossain2009">{{cite journal|last1=Aly|first1=Saida Abdel Regal|last2=Hossain|first2=Murad|last3=Bhuiyan|first3=Mohiuddin Ahmed|last4=Nakamura|first4=Takashi|last5=Nagatomo|first5=Takafumi|title=Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate|journal=Journal of Pharmacological Sciences|volume=110|issue=4|year=2009|pages=445–450|issn=1347-8613|doi=10.1254/jphs.09124FP}}</ref> Naftidrofuryl is also licensed for the treatment of [[intermittent claudication]] due to peripheral arterial disease.

Naftidrofuryl is marketed under a variety of [[trade name]]s, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.

Historically, it has been used to treat sudden [[idiopathic]] hearing loss and acute [[tinnitus]].<ref>http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm</ref>

Naftidrofuryl may be effective for relieving the pain of muscle [[cramp]]s.<ref name=Katzberg>{{cite journal |vauthors=Katzberg HD, Khan AH, So YT |title=Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology |journal=Neurology |volume=74 |issue=8 |pages=691–6 |date=February 2010 |pmid=20177124 |doi=10.1212/WNL.0b013e3181d0ccca |url=}}</ref>

==Adverse Effects==
Naftidrofuryl has been associated with [[nausea]], [[abdominal pain]] and [[rash]]. Rarely, [[hepatitis]] and [[liver failure]] have been reported.<ref name = MD>{{cite web|title=Naftidrofuryl Oxalate|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|date=14 January 2014|accessdate=6 August 2014|url=http://www.medicinescomplete.com/mc/martindale/current/9256-a.htm|editor=Brayfield, A}}</ref>

==See also==
* [[Ketanserin]]
* [[Sarpogrelate]]

==References==
{{reflist|30em}}

{{Peripheral vasodilators}}
{{Serotonergics}}

[[Category:5-HT2 antagonists]]
[[Category:5-HT2A antagonists]]
[[Category:Vasodilators]]
[[Category:Naphthalenes]]
[[Category:Tetrahydrofurans]]
[[Category:Carboxylate esters]]
[[Category:Amines]]


{{cardiovascular-drug-stub}}